New CEOs for Blackstone-backed Uniquity Bio and CNS cell provider Brainxell 

Uniquity Bio Inc., an immunology & inflammation company that secured a $300 million commitment from Blackstone Life Sciences last year, has hired Will Kane as president and CEO, succeeding co-founder and former CEO Brian Lortie, who stepped down in June. The company is advancing anti-TSLP mAb solrikitug, which it believes is more potent and may have dosing advantages over other members of the drug class, through Phase II trials in asthma, chronic obstructive pulmonary disease and eosinophilic esophagitis.

Fellow I&I company Recludix Pharma Inc. has promoted co-founder and SVP of Chemistry Brian Hodous to CSO. Hodous helped shape the chemistry platform that led to the company’s lead program, an IND-stage inhibitor of the STAT6 SH2 domain that is partnered with Sanofi (Euronext:SAN; NASDAQ:SNY). Recludix also hired Vivek Kadambi as SVP of non-clinical sciences and CMC, and expanded the role of VP, Portfolio, Program and Alliance Management Kristin Polsenski to include chief of staff to the CEO. Kadambi was most recently chief product development officer at IDRx Inc., which GSK plc (LSE:GSK; NYSE:GSK) acquired this year for $1 billion up front...